The designer of a clinical trial needs to make many assumptions about real-life practice based on prior knowledge. Simulation allows us to learn from experience by using the information obtained from a trial to improve the original estimators of population parameters. We propose using data from a previous trial to formulate assumptions that can be used to simulate trials and thus improve the design of new trials. To demonstrate our method, we used data from a real clinical trial which had been designed to evaluate cholesterol level changes as a surrogate marker for lipodystrophy in HIV patients. We were able to identify the optimal design that would have minimised the cost of a trial subject to a statistical power constraint which could then be used to design a new trial. In particular, we focused on three factors: the distribution of cholesterol levels in HIV patients, trial recruitment rates and trial dropout rates. We were able to verify our hypothesis that the total cost resulting from carrying out a clinical trial can be minimised by applying simulation models as an alternative to conventional approaches.
a b s t r a c t
The designer of a clinical trial needs to make many assumptions about real-life practice based on prior knowledge. Simulation allows us to learn from experience by using the information obtained from a trial to improve the original estimators of population parameters. We propose using data from a previous trial to formulate assumptions that can be used to simulate trials and thus improve the design of new trials. To demonstrate our method, we used data from a real clinical trial which had been designed to evaluate cholesterol level changes as a surrogate marker for lipodystrophy in HIV patients. We were able to identify the optimal design that would have minimised the cost of a trial subject to a statistical power constraint which could then be used to design a new trial. In particular, we focused on three factors: the distribution of cholesterol levels in HIV patients, trial recruitment rates and trial dropout rates. We were able to verify our hypothesis that the total cost resulting from carrying out a clinical trial can be minimised by applying simulation models as an alternative to conventional approaches.
In our findings the simulation model proved to be very intuitive and a useful method for testing the performance of investigators' assumptions and generating an optimal clinical trial design before being put into practice in the real world. In addition, we concluded that simulation models provide a more accurate determination of power than conventional approaches, thus minimising the total cost of clinical trials.
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Introduction
A randomised clinical trial can take a long time and be expensive, so optimised designs offer advantages in terms of alternative outcomes or surrogate endpoints, which in turn could reduce the cost of the trial while still maintaining high statistical power [1] [2] [3] [4] .
The design of a clinical trial depends, among other things, on prior knowledge. Trial designers must have an idea about the way that patients with specific characteristics will respond to different treatments, or the recruitment and dropout rates. These assumptions then form the basis of their designs for trial protocols. Some assumptions are based on prior knowledge, others reflect response to treatment expectations or anticipated phenomena such as patient trial attendance rates, compliance with treatment, dropouts and adverse events, all of which can affect trial results. However, any of these assumptions may be wrong or biased due to a lack of previous evidence or the uncertain nature of the variables.
Once a trial starts, the protocol cannot usually be changed, and cannot be tried and retried until an efficient trial has finally been run. If the designer's assumptions are accurate and s/he manages the trial strictly according to the protocol based on her/his assumptions, then the outcome of the trial will be reliable.
If the assumptions are wrong, the trial may yield unsatisfactory results. If this is the case, it is always too late to start again; the sponsor's investment of time, money, and effort may have been wasted and furthermore people may well have been subjected to unnecessary inconvenience, discomfort, and health risks.
A common assumption is that there are no dropouts and many previous methods for designing optimal clinical studies have largely overlooked patient dropout. This leads to underestimating the number or patients who need to be recruited to achieve a desirable statistical power, and, consequently, additional time and further financing are needed to recruit more patients. It is difficult to predict the results and characteristics of clinical trial designs that make this assumption using conventional statistical methods. Therefore, this paper describes a simulation model for a clinical trial that includes patients who drop out of a trial, potentially improving the design accuracy.
With simulation, our assumptions can form an explicitly defined basis for a model rooted in real-world practices. From here, we use powerful computing and statistical methods to generate data as if they had come from real patients. Simulation also allows us to test alternative models which highlight deviations from the designer's original assumptions. In addition, we can test alternative protocols and discover which one will be the most robust when studying alternative models. Each model, together with a protocol, can be used to generate data that might have come from a real trial, and this data can then be used to test the proposed analysis procedures to ensure that the original assumptions can be tested. In this paper we attempt to verify the hypothesis that the total cost resulting from carrying out a clinical trial can be minimised by using simulation models as an alternative to conventional statistical approaches.
Data and analysis results from a previous trial can provide a strong basis for the prior knowledge necessary to simulate a new trial and design an improved protocol, in turn, leading to stronger assumptions.
We used the Sigma for Windows general modelling and simulation package, which allows investigators to develop simulation models according to their own needs and specifications [5] . The computational model is available from the authors.
Data and methods
To test and demonstrate our method, we extracted data from the published database of a randomised clinical trial with HIV subjects [6] . The resulting analysis of this data was then used to design an improved trial.
The clinical trial
In the original trial 100 patients were recruited and 98 of these were randomly assigned to two treatment groups: (A) protease inhibitors and (B) nevirapine-based antiretroviral regime. The primary objective of this trial was to compare the efficacies of the two treatments in maintaining the suppression of plasma HIV-1 RNA and permitting progressive immunologic improvement in patients. Secondary objectives included assessing the impact of PI-sparing regimens on metabolic profiles, recording other adverse events and evaluating quality of life.
Changes in body shape were also assessed in patients with lipodystrophy once they began the nevirapine treatment, in comparison to subjects who continued receiving PI treatment. To do this, the trial investigator assessed the changes in the total cholesterol level at each follow-up visit. The justification for using the cholesterol level as a biomarker of lipodystrophy in HIV patients was based on their previous findings [7] . Similar findings by other investigators were cited by the trial authors. As shown in Fig. 1 , 100 patients were recruited in 12 months. Two patients were excluded from the trial and the rest were randomly assigned to either continue with treatment A or to switch to treatment B. This meant that 49 patients were allocated to A treatment group and 49 to the B treatment group. There were four follow-up visits, at three monthly intervals, to measure the cholesterol level of each patient (see Table 1 ). Twenty-nine and 26 patients finished the trial under treatments A and B, respectively. The mean cholesterol levels between the two treatments at the last visit were compared to assess whether there were significant differences between A and B at a level of 0.05.
In our analysis we propose two additional endpoints to measure the effects of both treatments (see Table 2 ). The two endpoints are:
(1) D: mean difference in cholesterol level between the last visit (v 4 ) and the baseline cholesterol level before the treatment (v 0 ). The number of patients considered in the analysis is the same as noted in Fig. 1 and Table 2 .
(2) M: mean difference between the average cholesterol level at the last visit the patient has attended and the baseline cholesterol level (M). In this case, the number of patients considered in the analysis was 47 and 48 for A and B, respectively. This endpoint takes into account data for patients who attend at least one visit during the trial follow-up period.
In addition, we calculated the time and the cost of the trial until its finalization. The assumed approximated values for the parameters of unit cost are:
(1) Fixed cost for participating centre = €6500 (C c ). 
The conventional approach
With the two proposed endpoints, D and M, we estimated the required sample size using formula 2. A simple adjustment to account for dropout probability can be made by dividing the sample size by the probability of patients who complete the trial. We calculated the probability of patient dropout from the trial using formula 1.
This equation subtracts from 1 the quotient of the remaining number of patients n at any given visit v (v = 1, 2, 3,. . .) divided by the number of patients n who dropped out in the previous visit. This equation is applied to calculate the dropout probabilities for patients under both treatments, A and B. This was the equation used in the simulation model. For both endpoints, we assume equal variance for both treatments represented by pooled standard deviation. A simple calculation of total cost of this trial can be made using formula 3, given the rate of recruitment and duration of follow-up.
where n is the required number of patients in each group, Z a is the value of Z corresponding to the risk of a (=1.96), Z b is the value of Z corresponding to the risk of b (=0.843), S is the standard deviation, d is the mean difference.
where Tcost is the total cost of the trial, n e is the number of patients in the new treatment, n c is the number of patients in the control treatment, t in is the time to include all patients, t f is the duration of follow-up.
The simulation model
We developed a simulation model to describe the process of enrolling patients and their follow-up visits in clinical trials that study continuous variables at discrete points of time, including dropout. We divided input parameters into two categories. The first includes the design parameters: endpoints, number of follow-up visits, number of centres and sample size. The second includes external parameters: selection rate, recruitment and dropout rate, cost of recruitment, cost of a visit, centre cost and opportunity costs of trial duration. The output variables are power, total duration of the trial and total trial cost.
As shown in the flow diagram in Fig. 2 , the model simulates the flow of patients through the trial from the time they arrive at the centre until they leave the trial. The flow of patients varies according to three probability distributions:
(1) The probability of inclusion, which determines if the patient is included or excluded. (2) The probability of treatment allocation, which determines if the patient is allocated to A treatment or to B treatment. (3) The probability of dropout after treatment allocation at each follow-up visit.
Recruitment sub-model
We assume that the monthly number of arrivals is a random variable with a Poisson distribution and that the time between arrivals is a random variable with an exponential distribution given by formula 4. The variable R denotes sampled values for i patients from a uniform distribution that has values between 0 and 1. The parameter rt denotes the mean inter-arrival time of the exponential distribution (rt = 1/N, N = number of arrivals). The parameter c denotes the number of centres participating in the trial. The total time of the recruitment is calculated as the sum of all inter-arrival times t for all simulated patients i from these distributions. The total cost is estimated by adding the cost by centre, the cost per patient and the cost of delay associated with longer trial duration.
Accordingly, the first patient arrives at the trial at time t and is screened to determine whether they meet the inclusion criteria and are subsequently enrolled in or excluded from the trial. If P in denotes the probability of inclusion, then the patient will be included if this probability is equal or less than the probability sampled from another uniform distribution R, as shown in Fig. 2 .
If the patient is included, then the patient will be randomly allocated to one of the two treatments (A or B) using another uniform distribution generator between 0 and 1, from which the patient has the P rnd probability of being allocated to treatment B. The patient then enters the follow-up sub-model as described below.
Follow-up sub-model
If this patient is allocated to treatment B, the corresponding baseline value will be generated from two random variables that follow normal distributions with 0 mean and s standard deviation plus the mean level, that is L i = Mean v + (dist 1 = N{0; s 1 }) + (dist 2 = N{0; s 2 }). At the subsequent visits of the follow-up, this model will generate the value of the studied variable (cholesterol level) from the value generated by dist 1 at the baseline visit and the value generated by dist 2 at each follow-up visit, plus the mean value that corresponds to the actual visit. Fig. 2 illustrates how these values are maintained throughout the simulation. Three statistical models were developed from the general model based on different assumptions regarding the cholesterol evolution patterns at the follow-up visit. The models are described below.
(1) Model 1: When this model is used to generate the cholesterol value at each visit, it considers the real-world model given by the data obtained from the trial (Table 1) . This model considers that the mean cholesterol level varies over visits, and is different for the two treatments. It also considers that the standard deviations between the two treatments are different, and specifies different standard deviations for each distribution. Therefore, the parameters, s 1 and s 2 , were estimated and calibrated using a method described in an earlier publication [8] . After generating the cholesterol value, the model applies the probability of a patient dropping out through another uniform distribution generator between 0 and 1. If the generated probability is equal to or less than the dropout probability, then the patient will continue receiving the treatment in the next visit; if not, the patient will drop out from the trial. In order to account for centrespecific dropout probability, we converted the probability of the trial shown in Table 1 , Pd(v), into the k(v) rate given by formula 5. Then, we used the rate found to calculate the intended probability depending on c centre, Pd(v, c), given by formula 6. This equation assumes that this dropout probability increases as the number of centres increases according to an exponential distribution.
where Pd(v,c) is the dropout probability at visit v (v = 0, 1, 2,. . .) and centre c (c = 1, 2, 3,. . .).
Assuming that the patient attends the next visit, then the value of the outcome variable (cholesterol level) will be updated according to the sum of the new mean level: the value generated from the first normal distribution Dist 1 at the baseline visit and the new value generated by the second normal distribution Dist 2. That is,
This process is repeated until the patient either reaches the last visit of the trial or the point when they drop out. In the case of patients allocated to treatment A, the model applies the same process according to the conditions related to this treatment, as shown in Fig.  2 . This procedure is repeated for all patients specified in the model.
Estimating the results of the model
When the last simulated patient of the given sample size reaches the last visit or drops out at an earlier visit, the model calculates the means and standard deviations of the selected endpoints for each treatment. The number of dropout patients is then calculated and recorded. The total duration and cost are also computed applying formula 3. This single simulation is repeated 100 times under different sequences of random numbers starting at 12,345 random seed and up to the 12,445, producing 100 independent data sets, each of the same sample size.
With 100 values of dropout probabilities produced by these simulations, we estimated the upper and lower levels of dropout probabilities from the dropout probabilities average observed in the trial (Table 3) .
One hundred means and standard deviations for each proposed endpoint and each treatment were estimated and recorded, and the total durations and costs were assessed for each repetition. At this point, we used the means and standard deviations to calculate the expected sampling means and standard deviations. Then, the t-statistic was calculated for each repetition of the simulation: dividing the differences in expected means by the expected sampling distribution standard deviation. To determine the expected statistical power, we calculated the proportion of repetitions that reach the acceptable significance level showing that B is better than A. Finally, the expected duration and cost of the trial were also estimated.
Number of simulations
The number of simulations is discretional. It is based on the desired precision of a parameter of interest. Since we are interested in estimating the power (p) of the trial, the number of simulations needed can be calculated so that the standard error (SE) of the power is minimised. Therefore, SE ðpÞ ¼ ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi ffi pð1 À pÞ=r p , where r is the number of simulations. If one wants to reduce the standard error to 0.04 for a power of 0.8, then 100 simulations would be required. With this error, the lower and upper values of 95% confidence interval of power can be calculated by IC 95 ¼ pAE Z 1Àa=2 Â SEðpÞ ¼ 0:8 AE 1:96 Â 0:04. We then have a 95% certainty that this power will be within the interval. Increasing the number of simulations produces a narrower confidence interval which means more precision in power estimation.
The investigated scenarios
The simulation model analysed the impact of each model and dropout assumptions on power, total duration and cost of a new trial. For each model, we created three scenarios, and for each scenario we ran different simulations using different parameters. Each simulation involved generating 100 independent simulated data sets for a given parameter combination.
The three scenarios were:
(1) Scenario 1. There are no dropouts from the trial: the trial is simulated at 1, 2, 3, 4, and 5 centres when using model 1, and is simulated at only one centre when using models 2 and 3. The recruitment rate and cost parameters used were those assumed by the trial. There are 100 replications for different sample sizes. (2) Scenario 2. This scenario is similar to scenario 1, but differs in that it considers dropout rates before and after patient allocation to one or other treatment. The dropout rate before randomisation is the inverse of inclusion probability, which is set to 0.98. After randomisation, the low, mean, and high dropout probabilities shown in Table 4 were considered depending on follow-up visits. We used a pre-protocol method (PP) to analyse the data resulting from the simulations. This method considers only patients who were randomly assigned to A and B treatment and finished the trial. (3) Scenario 3. This scenario replicates scenario 2, but uses the intention to treat method (ITT) for data analysis [9] . This method means that all randomised patients are considered who were evaluated for at least one visit after randomisation. If the patient drops out before the end of the trial, the study variable level (in this case, cholesterol level) at the last visit attended is assumed to be that of the last visit of the trial. Table 1 illustrates the mean and standard deviation cholesterol level measured at each trial visit. It also gives the number of patients that were randomised and the number still in the trial at each visit. The number of patients initially included in the original trial (98) was insufficient to achieve a statistically significant difference between the treatments at a level of 0.05.
Results

The conventional approach
The mean cholesterol levels between the two treatments at the last visit were compared, but this comparison is not relevant since the cholesterol level distribution parameters at the baseline visit are not equal (see Table 1 ). Therefore, the mean cholesterol level at the last visit was compared with the baseline level for each treatment on a separate basis. Again, there were no significant statistical differences in cholesterol level reductions. Consequently, the trial concludes that the hypothesis of switching to B treatment is better than continuing with A treatment is rejected.
Comparing the two treatment effects based on the two proposed endpoints, D and M, the results in Table 2 show that the trial still does not reach the statistical significance target level (P > 0.05). In addition, the confidence interval of every mean difference includes zero. Thus, all the analyses indicate that there is no significant difference between the effects of the two treatments.
This meant a delay of 24 months and an opportunity cost of about €298,000. The negative results of the trial could have been due to several possible reasons, such as too small a sample size, too short a duration, or simply that the treatment did not work. A review of general causes of negative results can be found in [10] .
According to the sample size determined by using formula (2), the two proposed endpoints could have reached a statistically significant difference between treatments with the desired power, but only with additional information. If the designer plans a new trial considering D as the endpoint of the trial, a sample size of 6887 patients is needed to reach a level of 0.05 statistical significance with a power of 0.8. If we assume a dropout probability of 43%, as in the original trial, this requires a sample size of 12,044 patients. Given the observed rate of recruitment, approximately 130 years and more than €6,000,000 are needed to enrol the number of patients required in one centre. Therefore, the trial would not be feasible.
However if the designer considers M as the endpoint of the trial, a sample size of only 613 patients is needed to show that the new treatment is better, meaning that a period of 84 months is needed for enrolment and follow-up. In this case, the trial would cost €587,000. If we consider that 9% of patients will dropout before the first follow-up visit, as shown in Table 2 , then this requires a sample size of 674 patients and a corresponding period of 92.9 months for the trial. In this case, the total cost would be €685,220. Once again, the trial may not be feasible due to time restrictions.
Modelling approach
Whenever one develops a model, the first question to ask is whether its results are internally validated or not. Table-S1 gives the statistical results of cholesterol level for model 1, assuming no dropout rates and given different sample sizes. As expected, the sampling standard deviation decreases as the number of patients increases both for D and M endpoints. Comparing them with those of the clinical trial, we found that the model performs well replicating the results of the trial with an acceptable error level. The relative errors of simulated and observed parameter standard deviations are below 10%. The standardised differences between observed and simulated means are also below 10%. We also quantified the coverage assessment of the model using the 95% confidence interval. We estimate the proportion of times that the 100 simulated confidence intervals contain the parameter of interest, which is the difference between the two treatments. We found that 98% and 99% of simulated intervals contained this parameter for the D and M endpoints, respectively. The two standard deviations, s 1 and s 2 were estimated at 38 and 34 for treatment A, and 36 and 27 for treatment B. Therefore, the results of the model are valid and the model can then be used to represent an experiment. Fig. 3 illustrates the expected power of model 1 under scenario 1 and 2. In the case of endpoint D, we found that the power does not change when increasing the sample size (lower lines). However, with endpoint M, it increases as sample size increases. When dropouts are considered under scenario 2, higher power was shown in all cases of dropout rates. Fig. 4 illustrates the expected duration (TD, in months) and cost (€) depending on sample sizes and centres.
Figs. 5-7, show the expected power of model 1 under scenario 3, for low, mean and high dropout rates, respectively. For both endpoints, these rates verify that the power increases as sample size increases for any number of centres. Moreover, the expected power increases as the dropout rate increases. As expected, the total cost is reduced by increasing the number of centres and dropout. This is because dropout patients from the trial did not attend all the required visits. The expected duration decreases as the number of invF2, the inverted formula 2 for power calculation; D-P, expected power considering D as the endpoint of the trial; M-P, expected power considering M as the endpoint of the trial; TD, expected total duration of the trial; TCost, expected total cost of the trial.
centres increases, irrespective of whether dropout rates are high or low. This is because (1) all patients who participated in the trial are screened; (2) screened patients are enrolled immediately; and (3) the follow-up visits are fixed. Using model 2, endpoint M continues to be more efficient than endpoint D (see Figure-S1 and Figure-S2 ), however, D is more efficient than M using model 3 (see Figure-S3 and Figure-S4 ). The results of these two models show that the expected power decreases as the dropout increases, and the total durations and costs were reduced for all dropout assumptions for both models and scenarios. However, the reduction of power must be compensated for by adding the information for new patients, which means investing more time and money.
Furthermore, Table-S2 illustrates that the relative difference in the number of allocated patients between the two treatments depending on the centre would result only in a minor deviation. These results ensure that the simulation model achieves a good balance which results in a high degree of precision regarding power estimation.
Comparing the conventional vs. the modelling approach
Assuming M to be the endpoint of the trial, and considering the mean probabilities of dropout, according to the conventional approach 674 patients are needed to attain a power of 0.8 for a significant level of 0.05 to conclude that there is a significant difference between the two treatments. The expected cost resulting form the trial would be €685,000.
However, if we apply the modelling approach we can see that 600 patients would be enough to attain the same objective at a lower cost. Carrying out the trial at one centre with 600 patients, we would obtain the expected results illustrated in Table 4 . The conventional approach represented by the inverted formula (2) (invF2) estimates that the trial would achieve a power of 0.75 at a cost of €619,000 if M is used to measure the efficacy of the trial. However, the modelling approach estimates that a power of 0.85 would be achieved at a lower cost (€606,000). Moreover, assuming that the two approaches attain the target significance level of difference at the same power, as shown in Table 4 for D endpoint with scenario 2, the cost is minimised by simulation because it takes into account the patients that dropped out at different moments during follow-up, as would happen in real clinical trials.
While the conventional approach is not able to consider multicentre trials, the simulation model provides results that are even more efficient, as shown in Table 4 . The power is maintained high enough with the M endpoint, it is increased with the D endpoint according to intention to treat, and duration and cost are minimised.
Discussion and conclusions
A general simulation model was developed using data and results of a clinical trial that had already been run to show how new clinical trials could be designed better. Our assumptions form the basis of a model of the real world, for which we used powerful computing and statistical methods to generate data as if they had come from real patients.
The trial, as originally designed, showed no significant differences between the two treatments; consequently, the time and money invested in it have been lost, as the trial will not lead to a better treatment for the patients.
Trial data and the assumed two endpoints enable us to plan a new trial to test the results with additional information. We estimate the required sample size, the time and cost using the conventional approach based on the results of the trial and the assumptions of the designer. This approach does not consider cost factors that determine the efficiency of the trial, and furthermore, many assumptions have to be made. Formula (2) assumes constant changes and equal standard deviations of the outcome of the two compared treatments. Nevertheless, when the variances are different, the assumption that they are equal leads to wrong estimates of sample size or of the power of the trial. The correlations between measurements at different visits are not taken into account, and thus these measurements are treated as independent. This, again, leads to a misestimating of the real effects of the trial and thus of the power of the trial [11] . Moreover, if the designer of the trial wants to account for centre-specific dropout probabilities, the conventional approach to power estimation cannot be applied. Formulas for approximating the results considering these characteristics of clinical trial design are either not available or difficult to apply.
In these situations, computer simulation is the only alternative. It has been applied to different situations to determine sample size for clinical trials which investigate treatment differences in repeated measurements when a continuous variable is evaluated over fixed periods. Ahu et al. [12] applied a model assuming that changes in the mean response variable are constant over time. Patient dropout probability is independent and uniformly distributed over a given period. Mayer-Hamblett and Kronmal [13] used simulation to study a continuous variable when response variable changes are not constant over given periods. They investigated optimal endpoints that minimise sample size while still detecting significant treatment differences. However, these papers did not consider the dropout probabilities nor the effect of multi-centre trials on power estimation or cost.
The simulation results showed that whether dropout rates are assumed or not, defining the endpoint in terms of the mean difference between the average of the four visits and the baseline cholesterol levels is more efficient than using the mean difference in cholesterol levels between the last visit and the baseline cholesterol. This is likely to be the case whenever cholesterol level changes are not constant over time. However, when the changes are constant, the results showed that the mean difference between the last and the baseline cholesterol level is more efficient. This is similar to the findings of a previous study [13] . We can be therefore concluded that, if an efficient endpoint is used to measure the difference between the two treatments, power, duration and costs of the trial will be optimised.
Conventional approaches to clinical trial design, such as formula (2), usually predict that the power of the trial will be reduced when dropout rates are considered. However, we have shown that this prediction is not always true. If changes in mean cholesterol were variable over a given period, we found that the power increased when considering dropout patients. It is clear that when formula (2) is used to adjust sample size, it considers only overall probability of dropout patients and cannot take into consideration timedependent probabilities, such as those shown in Table 3 . This will overestimate power and sample size, and, consequently, duration and cost. Moreover, the total cost by itself is overestimated because the conventional approach for estimating sample size or power ignores the cost of patients who drop out from the trial before the last or follow-up visits. As we have shown, the simulation model provides a more accurate adjustment of power for a smaller sample size, and the total cost is also minimised for any given dropout probability.
Furthermore, one of the problems of modelling multi-centre trials, especially in small trials, is the difficulty of ensuring a balanced treatment-patient allocation. The most common approach adopted to ensure an optimal balance between groups in small trials, is to use allocation by minimisation [14] . This approach consists of allocating patients to treatments groups according to a set of characteristics. The allocation is not totally random in practice since it is based on random and deterministic components depending on the characteristics of patients who have been allocated to treatments [15] .
In this study, we used a simple randomization approach to allocate patients to the two treatments, and we applied the method of repetitions to estimate the results. Assuming a multi-centre trial, we found that this method achieved a high balance between centres. Patients are allocated to the two treatments with minor variations, depending on the centre. This method is intuitive and is easy to apply, particularly when there are many factors in large or small trials. In addition, the process is totally random and it can be extended to account for more variables such as gender and patient's age. However, we are constrained by computing time and cost because many replications are needed to reduce variability of the results. One can use supercomputing to reduce the cost of variability reduction, and consequently, to reduce the uncertainty of multi-centres clinical trial results.
We constructed a general model in such a way that parameters can easily be modified in order to analyse alternative continuous variables and/or scenarios and assumptions. The cholesterol variable used in the model can be changed to other variables, such as CD4 and viral load. Therefore, mean, variance and correlation structures can be specified according to the new variable. Recruitment rate, probability of inclusion, dropout rates and cost can be modified to produce new analyses. The model can simulate the trial for different numbers of follow-up visits in order to determine the optimal number of repeated measures, subject to power, duration or cost constraints. This will enable the designer to estimate the number of visits needed for acceptable statistical power. Thus, if the designer modifies the parameters, the model will generate new results. The impact of these modifications on the results can be quantified, and therefore the combination of parameters that provides optimal results can be anticipated before the real-world trial is carried out. We have deliberately omitted some variables that would be included in a thorough study, such as viral load, CD4 counts and clinical outcomes, to simplify the description of our method.
In conclusion, simulations can be applied easily to real situations of clinical trials to test the performance of investigators' assumptions. Simulations can also be used to reveal the optimal design parameters for a clinical trial before it is put into operation in the real world. We have shown how simulation avoids the limitations of the conventional approach to clinical trial design by providing a more accurate determination of power, and minimising the total cost of clinical trials.
